× Trade Agreements and Direct-to-Consumer Advertising of Pharmaceuticals

× BRIC Health Systems and Big Pharma: A Challenge for Health Policy and Management

× Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries 

× Medication Errors Associated With Adverse Drug Reactions in Iran (2015-2017): A P-Method Approach 

× Universal Pharmacare in Canada: A Prescription for Equity in Healthcare

× National Pharmacare in Canada: Equality or Equity, Accessibility or Affordability Comment on “Universal Pharmacare in Canada: A Prescription for Equity in Healthcare”

× It’s Time to Finally Kill the Zombies Comment on “Universal Pharmacare in Canada”

× The Challenges of Canadian Pharmacare Are More Complicated Than Acknowledged Comment on “Pharmacare in Canada”

× Separated at Birth: The Politics of Pharmacare for All in Canada and Medicare for All in the United States Comment on “Universal Pharmacare in Canada”

× Understanding the Battle for Universal Pharmacare in Canada Comment on “Universal Pharmacare in Canada”

× Cheaper Medicines for the Better Off? A Comparison of Medicine Prices and Client Socioeconomic Status Between Chain and Independent Retail Pharmacies in Urban India

× Evaluation of the Participation of Community Pharmacists in Primary Healthcare Services in Nigeria: A Mixed-Method Survey

× Evaluation of Pharmacovigilance System in Iran

× Impact of Non-pharmaceutical Interventions on the Control of COVID-19 in Iran: A Mathematical Modeling Study

× The Effects of Cost Containment and Price Policies on Pharmaceutical Expenditure in South Korea

× Epidemics, Lockdown Measures and Vulnerable Populations: A Mixed-Methods Systematic Review of the Evidence of Impacts on Mother and Child Health in Low-and Lower-Middle-Income Countries

× Donations Made and Received: A Study of Disclosure Practices of Pharmaceutical Companies and Patient Groups in Canada

× Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe

× More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry’s Role in Widening the Access Gap

× Commercializing Personal Health Information: A Critical Qualitative Content Analysis of Documents Describing Proprietary Primary Care Databases in Canada

× Characteristics and Distribution of Scholarship Donations From Pharmaceutical Companies to Japanese Healthcare Institutions in 2017: A Cross-sectional Analysis

× Phase IV Drug Trials With a Canadian Site: A Comparison of Industry-Funded and Non-Industry-Funded Trials